Our results indicate that the MyD88 pathway in myeloid cells may limit RT-mediated immune control of pancreatic cancer and agonists avoiding inflammatory MyD88 signaling or myeloid-specific MyD88 inhibition may be alternative strategies to improve outcomes. The gene discussed is MYD88; the disease is familial pancreatic carcinoma.